G. Schett

Adult-onset chronic nonbacterial osteitis mimicking refractory axial psoriatic arthritis: successful treatment with combined IL-1/IL-17 inhibition: a case report and brief literature review

We report a 46-year-old man with palmoplantar pustular psoriasis and severe axial inflammation who was initially diagnosed with refractory axial psoriatic arthritis. Despite sequential treatment with multiple biologic and targeted therapies, disease activity persisted. Reassessment based on anterior chest wall involvem...

The synergistic impact of granulocytic myeloid-derived suppressor cells and innate lymphoid cells in systemic sclerosis.

OBJECTIVE Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid-derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc-associated fibrosis and their interactions with other immune cell...

Difficult-to-treat systemic lupus erythematosus: from refractory disease to a multidimensional clinical trajectory.

Difficult-to-treat (D2T) systemic lupus erythematosus (SLE) is increasingly recognised in clinical practice but is still conceptually underdeveloped. In contrast to rheumatoid arthritis and psoriatic arthritis, for which formal D2T frameworks have been proposed, SLE still lacks a multidimensional model capable of captu...

Use of advanced therapies in systemic lupus erythematosus: a retrospective single centre analysis based on disease phenotypes.

Advances in imaging for systemic sclerosis.

A narrative review aims to provide an up-to-date overview of available and emerging imaging tools that may help discriminate activity from damage across organ systems involved in SSc, with a specific focus on early fibrotic and inflammatory manifestations.

Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series

Data support anti-CD19 CAR T cell therapy as a durable, effective intervention for refractory MG and warrant further evaluation in prospective controlled clinical trials.

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

CD19 CAR T cells showed acceptable short-term tolerability in patients with treatment-refractory RA, justifying further evaluation, and the primary endpoint was met, allowing advancement to phase 2.